A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer

Brief description of study

You can participate in this study if you are diagnosed with cancer of the colon or rectum and your cancer progressed after or intolerant to the standard of care therapy. The purpose of this study is to determine the efficacy and safety of XL092 (anti-cancer drug) plus atezolizumab (a type of immunotherapy drug, It helps to stimulate the body's immune system to fight cancer). Versus regorafenib (an FDA-approved anti-cancer drug) in patients with cancer of the colon or rectum, who have progressed after or are intolerant to the standard of care therapy. The study also determines how the body handles these study drugs, and how the study drugs are absorbed (taken in by the body), metabolized (broken down by the body), distributed (circulated in the body), and eliminated (passed out of the body). The patients will be monitored and taken care of while on these medications during the entire study period.


Clinical Study Identifier: s22-00058
ClinicalTrials.gov Identifier: NCT05425940
Principal Investigator: Paul E. Oberstein.
Other Investigators: Daniel J Becker, Marta Wioleta Wronska, Jennifer Chuy, Kristen Spencer, Monica Rivera, Keriann M Scavone, Nina Beri, Michael Shusterman, Anastasiya Apanasyuk, Rafael Winograd, Shun Yu, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.